药物重定位方法对抗冠状病毒：潜在药物和药物靶点。
Drug repurposing approach to combating coronavirus: Potential drugs and drug targets.
机构信息
Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas, USA.
Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas, USA.
出版信息
Med Res Rev. 2021 May;41(3):1375-1426. doi: 10.1002/med.21763. Epub 2020 Dec 5.
In the past two decades, three highly pathogenic human coronaviruses severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus, and, recently, SARS-CoV-2, have caused pandemics of severe acute respiratory diseases with alarming morbidity and mortality. Due to the lack of specific anti-CoV therapies, the ongoing pandemic of coronavirus disease 2019 (COVID-19) poses a great challenge to clinical management and highlights an urgent need for effective interventions. Drug repurposing is a rapid and feasible strategy to identify effective drugs for combating this deadly infection. In this review, we summarize the therapeutic CoV targets, focus on the existing small molecule drugs that have the potential to be repurposed for existing and emerging CoV infections of the future, and discuss the clinical progress of developing small molecule drugs for COVID-19.
在过去的二十年中，三种高致病性人类冠状病毒——严重急性呼吸综合征冠状病毒（SARS-CoV）、中东呼吸综合征冠状病毒，以及最近的 SARS-CoV-2，导致了严重急性呼吸道疾病的大流行，其发病率和死亡率令人震惊。由于缺乏特异性抗-CoV 治疗方法，目前 2019 冠状病毒病（COVID-19）的大流行对临床管理构成了巨大挑战，并突出表明迫切需要有效的干预措施。药物再利用是一种快速而可行的策略，可以确定有效药物来对抗这种致命感染。在这篇综述中，我们总结了治疗 CoV 的靶点，重点介绍了具有再利用潜力的现有小分子药物，这些药物可能用于未来现有的和新兴的 CoV 感染，并讨论了开发 COVID-19 小分子药物的临床进展。
Zotero 插件